Images List Premium Download Classic

Pharmaceutically Acceptable Salts

Pharmaceutically Acceptable Salts-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Peptide macrocycles against acinetobacter baumannii
August 17, 2017 - N°20170233437

Wherein x1 to x8 and r1 to r8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (i), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by acinetobacter baumannii.
Novel compounds
August 17, 2017 - N°20170233430

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous ...
Inhibitors of hif prolyl hydroxylase
Msd R&d (china) Co., Ltd.
August 17, 2017 - N°20170233412

The present invention concerns compounds of formula i or pharmaceutically acceptable salts thereof, which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel compounds as ror gamma modulators
Glenmark Pharmaceuticals S.a.
August 17, 2017 - N°20170233380

The present disclosure is directed to compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein ring a, ring b, l, r1, r2, r3, r4, r5, ra, rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (rorγt). These compounds prevent, inhibit, or suppress the action ...
Aryl and heteroaryl fused lactams
Glenmark Pharmaceuticals S.a.
August 17, 2017 - N°20170233368

In which r1, r2, u, v, l, m, r5, m, x, y and z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
Neuroactive substituted cyclopent[a]anthracenes as modulators for gaba type-a receptors
Washington University
August 17, 2017 - N°20170233356

The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to gaba function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Aza-heteroaryl compounds as pi3k-gamma inhibitors
Epizyme, Inc.
August 17, 2017 - N°20170232016

And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
Sage Therapeutics, Inc.
August 17, 2017 - N°20170232006

The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to gaba function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
Compounds for use in treating acute coronary syndrome and related conditions
Vitae Pharmaceuticals, Inc.
August 17, 2017 - N°20170231992

Provided herein are compounds and pharmaceutically acceptable salts thereof that are useful therapeutics for acute coronary syndrome and related disorders.
Compounds for inflammation and immune-related uses
Synta Pharmaceuticals Corp.
August 17, 2017 - N°20170231984

The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and ...
Amderma Pharmaceuticals, Llc
August 17, 2017 - N°20170231932

The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition ...
Inhibitors of pi3k-delta and methods of their use and manufacture
Exelixis, Inc.
August 10, 2017 - N°20170226131

The invention is directed to compounds of formula i: and pharmaceutically acceptable salts or solvates thereof as well as methods of making and using the compounds.
Inhibitors of hif prolyl hydroxylase
Msd R&d (china) Co., Ltd.
August 10, 2017 - N°20170226120

The present invention concerns compounds of formula i or pharmaceutically acceptable salts thereof, which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tied-back benzamide derivatives as potent rock inhibitors
Bristol-myers Squibb Company
August 10, 2017 - N°20170226105

The present invention provides compounds of formula (i) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Methods and compositions for gamma-glutamyl cycle modulation
Cancer Research Technology, Llc
August 10, 2017 - N°20170226070

The present disclosure provides pharmaceutical compositions comprising gamma-glutamyl cycle inhibitors (ggci) and certain pharmaceutically acceptable salts thereof, and methods of use.
Piperazine derivatives as liver x receptor modulators
Vitae Pharmaceuticals, Inc.
August 10, 2017 - N°20170226067

Provided are novel compounds of formula (i): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver x receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver x receptor. Also provided are the compounds of formula (i) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, alzheimer's disease, dermatitis, dyslipidemia, cancer ...
Prodrugs comprising an aminoalkyl glycine linker
Ascendis Pharma A/s
August 10, 2017 - N°20170224829

The present invention relates to novel prodrugs of primary or secondary amine- or hydroxyl-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs and the use of said prodrugs.
Prmt5 inhibitors and uses thereof
Glaxosmithkline Intellectual Property Development Limited
August 10, 2017 - N°20170224685

Described herein are methods of treating cancer using one or more prmt5 inhibitors, for example using one or more compounds of formulae (1-5) or (a-f), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more prmt5 inhibitors, for example using one or more compounds of formulae (1-5) or (a-f), pharmaceutically ...
Ship1 modulators and methods related thereto
Glaxosmithkline Intellectual Property Development Limited
August 10, 2017 - N°20170224682

N, r1, r4a, r4b, r5, r7 and r8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as ship1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from ship1 modulation. Compositions comprising a compound of formula (i) in combination ...
Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
Glaxosmithkline Intellectual Property Development Limited
August 10, 2017 - N°20170224663

Is administered to the subject or is contacted with the cancer cell. Compounds of formula (i) have substituents r1, r2 and r3 which have the meanings given in the specification, and pharmaceutically acceptable salts thereof.
Compounds for use in treatment of mucositis
Cellceutix Corporation
August 10, 2017 - N°20170224640

The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.
Loading